Aplasia of Lacrimal and Salivary Glands (ALSG)

Aplasia of Lacrimal and Salivary Glands (ALSG) is a rare, inherited condition where the tear-making glands near the eyes (lacrimal glands) and the saliva-making glands in the mouth (parotid, submandibular, sublingual) never fully form or are missing. Because of this, people have very dry eyes and a very dry mouth from childhood or early adult life. The condition can occur alone or as part of an overlapping syndrome called Lacrimo-Auriculo-Dento-Digital (LADD) syndrome, which can also affect ears, teeth, and fingers. ALSG is usually autosomal dominant, meaning a change in one copy of a gene is enough to cause the condition. Variants in FGF10 are well documented in ALSG; related LADD cases also involve FGFR2 and FGFR3. Genetic Diseases Center+4Nature+4PubMed+4 FGF10-FGFR2 signaling is important for branching and growth of exocrine glands before birth. When this pathway is disrupted, the lacrimal and salivary systems may be partially developed (hypoplasia), narrowed or blocked (atresia), or absent (aplasia). The result is poor tear film on the eye surface and reduced or absent saliva in the mouth. Dry eyes can damage the corneal surface; dry mouth raises the risk of cavities, gum disease, oral infections, and problems with swallowing, taste, and speech. Rare Diseases+1

Aplasia of the lacrimal and salivary glands means that the tear-making glands (lacrimal glands) and the saliva-making glands (salivary glands) are missing, under-developed, or blocked from birth. Because the body produces too little (or no) tears and saliva, people have dry, irritated eyes and a very dry mouth. This dryness can lead to eye infections or damage on the eye surface, and it can cause mouth problems like trouble chewing and swallowing, tooth decay, gum disease, and oral infections. In many people, this problem appears as part of a genetic condition called Lacrimo-Auriculo-Dento-Digital (LADD) syndrome, which also affects ears, teeth, and fingers. In others, only the tear and salivary glands are involved. Medical imaging (such as MRI or CT) can show that the glands are missing or small, and simple office tests can show very low tear or saliva flow. Orpha+2PMC+2

Other names

• ALSG – Aplasia of the Lacrimal and Salivary Glands

• Lacrimo-auriculo-dento-digital (LADD) syndrome – a genetic syndrome that commonly includes aplasia or hypoplasia (under-development) of lacrimal and salivary glands

• Lacrimal gland agenesis / hypoplasia – missing or under-developed tear glands

• Salivary gland agenesis / aplasia / hypoplasia – missing or under-developed salivary glands

• Congenital alacrima – born with very low or absent tears
  These names describe overlapping findings. LADD is a broader syndrome; ALSG can be an isolated form or part of LADD. Mutations in FGF10, FGFR2, or FGFR3 are classic genetic causes. PMC+1

Types

1. Isolated ALSG – only the tear and salivary glands are affected. People mainly have dry eyes and dry mouth without the full LADD features. Imaging confirms missing or tiny glands. PMC

2. ALSG as part of LADD syndrome – along with gland aplasia, people may have ear shape changes or hearing loss, small or missing teeth, enamel problems, and finger/toe differences. Genetic testing may show variants in FGF10, FGFR2, or FGFR3. PMC

3. Unilateral vs bilateral involvement – one side (unilateral) or both sides (bilateral) may be missing or small. Bilateral cases usually cause more severe dryness. ScienceDirect

4. Complete vs partial aplasia – all major glands absent (complete) versus only some glands missing or small (partial). Partial forms may still cause significant symptoms. PMC

5. Associated lacrimal drainage anomalies – people may also have absent puncta (the tiny eyelid openings), canalicular atresia, or nasolacrimal duct problems, which change tear drainage and can complicate care. PubMed

Causes

Each “cause” here explains why someone might have aplasia or severe under-development. Many are genetic or developmental and start in the womb.

1. Autosomal dominant genetic variants (classic ALSG/LADD)
   Changes in genes that guide gland branching—especially FGF10, FGFR2, or FGFR3—can disrupt normal growth of lacrimal and salivary glands. This is the best-studied cause and often runs in families. PMC+1

2. New (de novo) mutations
   Sometimes the genetic change is new in the child and not present in either parent. The clinical picture can be identical to inherited cases. PMC

3. Defective branching morphogenesis pathways
   Glands form by repeated branching. Disruption of the TBX4–FGF10–FGFR2 signaling pathway can halt terminal branching, leaving tiny or absent glands. Nature

4. Syndromic association (LADD)
   When the same developmental pathways also shape ears, teeth, and limbs, a multi-system picture appears (LADD). The gland aplasia is one component of the syndrome. PMC

5. Associated punctal or canalicular atresia
   If the eyelid puncta or tiny tear channels fail to develop, it often travels with gland under-development because the same region and timing are involved. PubMed

6. Isolated congenital lacrimal gland agenesis
   Rarely, only the lacrimal gland fails to form, with otherwise normal mouth glands. Imaging confirms absence. PMC

7. Isolated congenital salivary gland agenesis
   All (or some) of the major salivary glands can be missing without eye involvement. People present with severe dry mouth and dental complications. PMC+1

8. Minor salivary gland aplasia
   Small salivary glands scattered in the mouth may also be reduced, further lowering moisture and worsening oral health. PMC

9. Chromosomal or broader developmental variants
   Some people show gland aplasia along with other congenital differences, suggesting broader developmental field effects beyond the classic LADD genes. (Inference from reviews of heterogeneous cases.) PMC

10. In-utero growth disturbances
    Early fetal insults—vascular, infectious, or toxic—may interrupt gland bud formation in rare cases, leaving aplasia or hypoplasia. (General developmental mechanism discussed across agenesis reviews.) AAPD

11. Down syndrome association (rare)
    A review has described major salivary gland aplasia/hypoplasia among people with Down syndrome; this is unusual but documented. Wiley Online Library

12. Ectodermal development disorders (broad group)
    Because lacrimal and salivary glands arise from ectoderm, ectodermal dysplasia-like biology can theoretically affect them; selected case series report overlapping features. (Supportive but varied literature.) PMC

13. Microdeletions or gene rearrangements
    Beyond single-letter mutations, larger deletions (for example, removing exons of FGF10) can cause the same phenotype. Nature

14. Familial clustering without known gene
    Some families show the phenotype but standard panels are negative; undiscovered genes or regulatory elements may be involved. (Conclusion drawn from heterogeneous case reports.) PMC

15. Teratogen exposure hypothesis
    Severe fetal exposures could, in theory, impair gland bud formation. This is speculative and not a routine cause, but discussed as a possible mechanism in agenesis reviews. AAPD

16. Vascular disruption sequence (rare)
    A transient blood-supply problem during organ budding may stop development locally. This is a proposed mechanism in various organ agenesis reports. AAPD

17. Embryologic field defects
    If the tissues that form structures of the first branchial arch are disturbed, multiple head-and-neck glands and ducts can be affected together. (Embryology-based rationale echoed in reviews.) PMC

18. Unknown / idiopathic
    Even after testing and imaging, many cases remain unexplained; clinicians diagnose based on the structural absence and symptoms. PMC

19. Modifier genes and variable expressivity
    The same FGF10-pathway mutation can look mild in one person and severe in another, suggesting other genes or environment modify the final picture. Nature

20. Overlap with airway and lung branching biology
    The FGF10 pathway also shapes lung branching. Families with FGF10 variants show variable features across organs, reinforcing a shared developmental mechanism. Nature

Symptoms

1. Persistently dry eyes (alacrima) – burning, stinging, or scratchy eyes because there are not enough tears to coat and protect the surface. Orpha

2. Stringy or thick eye discharge – the eye tries to compensate for lack of watery tears with mucus, which can blur vision or crust the lashes.

3. Light sensitivity (photophobia) – the dry corneal surface is easily irritated by light.

4. Recurrent eye infections or keratitis – dryness weakens the eye’s defenses, leading to redness, pain, or even corneal damage. Orpha

5. Feeling like “sand in the eyes” – a gritty foreign-body sensation is very common with severe dryness.

6. Difficulty wearing contact lenses – lenses feel uncomfortable and can worsen surface injury.

7. Dry mouth (xerostomia) – need to sip water often; food sticks to the mouth; speech may be harder after talking. PubMed

8. Trouble chewing and swallowing dry foods – saliva helps moisten and start digestion; without it, eating can be slow and tiring.

9. Altered taste – saliva carries taste molecules; low flow can blunt flavors.

10. Bad breath – saliva controls oral bacteria; low flow can cause halitosis.

11. Frequent dental caries (cavities) and enamel erosion – saliva buffers acids and protects teeth. With aplasia, tooth decay can be severe and early. PubMed+1

12. Oral infections (thrush) and inflamed mucosa – dry mucosa cracks and gets infected more easily. AAPD

13. Swollen or “missing” gland areas on exam – a doctor may feel no normal salivary gland bulk where it should be, or see absent puncta in the eyelids. PubMed

14. Hearing, dental, or finger differences (in LADD) – if ALSG is part of LADD, there may be hearing changes, small or misshapen teeth, and finger anomalies. PMC

15. Eye watering “paradoxically” – if drainage openings are absent, tears may overflow (epiphora) even when overall tear production is poor, because tears cannot drain properly. PubMed

Diagnostic tests

A) Physical examination (at the clinic)

1. Eye surface inspection with slit-lamp
   The eye doctor looks for dryness signs: reduced tear lake, filaments, punctate staining, and signs of keratitis. This exam also finds eyelid margin disease that can worsen dryness.

2. Evaluation of puncta and canaliculi
   The clinician checks if the small eyelid openings (puncta) exist and are patent. Some people with ALSG have absent puncta or canalicular atresia, which alters drainage. PubMed

3. External palpation of salivary glands
   The doctor gently palpates the parotid and submandibular regions. In aplasia, there may be little or no palpable gland tissue or outflow from ducts.

4. Oral cavity and dentition check
   Look for rampant caries, enamel erosion, candidiasis, angular cheilitis, and dry, sticky mucosa—common consequences of severe salivary hypofunction. AAPD

5. Ear, teeth, and hands exam (if LADD suspected)
   Because LADD can involve ears (shape or hearing), teeth (small, missing, or enamel defects), and digits (shape differences), clinicians examine these sites as clues to a syndromic cause. PMC

B) Manual / bedside tests

6. Schirmer test
   A small paper strip is placed under the lower eyelid to measure tear production over 5 minutes. Very low wetting supports severe tear deficiency.

7. Tear film break-up time (TBUT)
   A dye is placed in the eye, and the clinician measures how quickly dry spots appear on the cornea. A short time indicates an unstable tear film.

8. Ocular surface staining
   Fluorescein or lissamine green dyes highlight damaged areas on the cornea and conjunctiva. Severe staining supports clinically important dryness.

9. Whole-mouth sialometry (unstimulated saliva flow)
   You quietly spit into a pre-weighed tube for several minutes. Unstimulated flow ≤ 0.1 mL/min is typically considered very low. PMC+1

10. Stimulated sialometry
    You chew paraffin or gauze and spit for 5–15 minutes. Stimulated flow ≤ 0.7 mL/min is abnormally low. These cut-offs are widely used in research and clinics. PMC

11. Gland duct massage
    Gentle pressure over parotid or submandibular areas while observing Stensen’s and Wharton’s duct openings can show absent or minimal saliva output.

12. Taste testing (including electrogustometry in specialized centers)
    Because saliva carries taste molecules, severe dryness can blunt taste; formal tests can document reduced sensitivity.

C) Laboratory / pathological tests

13. Basic autoimmune screen (to rule out other causes of dry mouth/eyes)
    Blood tests like ANA, anti-SSA/Ro, and anti-SSB/La help exclude Sjögren’s and other autoimmune diseases when structure is normal. Note: in ALSG, the problem is structural absence, so autoantibodies are usually negative. (Used to differentiate, not diagnose ALSG.) BioMed Central

14. Salivary composition or culture (selected cases)
    If there is some saliva, labs may analyze electrolytes or culture for Candida; this helps manage complications but does not “prove” aplasia.

15. Genetic testing (targeted panels or exome)
    Testing for FGF10, FGFR2, FGFR3 variants supports a syndromic diagnosis (LADD/ALSG). Not all clinics have access; results may still be negative in some families. PMC

D) Electrodiagnostic tests

16. Blink reflex studies (specialized)
    These assess trigeminal and facial nerve pathways that control blinking and eye protection. Abnormalities suggest a neural contribution to surface dryness but are not specific to ALSG.

17. Electrogustometry
    Measures taste nerve thresholds electrically; reduced taste sensation may reflect severe oral dryness rather than nerve disease, but can help document functional impact.

E) Imaging tests

18. Orbital ultrasound, CT, or MRI for lacrimal glands
    These tests visualize whether lacrimal glands are present, small, or absent, and look for associated drainage anomalies. MRI and CT are widely reported for this purpose. PMC+1

19. MR or CT dacryocystography (lacrimal drainage imaging)
    Contrast-assisted MRI or CT outlines the puncta, canaliculi, sac, and nasolacrimal duct to detect atresia or obstruction—valuable for surgical planning. AJNR+1

20. Salivary gland imaging (ultrasound, MRI) or scintigraphy
    Neck ultrasound and MRI can show absent or tiny parotid/submandibular glands. Nuclear medicine scintigraphy assesses uptake and excretion when residual tissue exists. Together, these methods confirm structure and function. PMC

Non-pharmacological treatments (therapies & others)

(Each item includes a 150-word description, purpose, and mechanism.)

1. Preservative-free artificial tears (frequent use).
   What/How: Single-use, preservative-free lubricating drops used many times a day. Purpose: Soothe irritation, restore moisture, and protect the corneal surface. Mechanism: Replaces the missing watery component of the tear film and improves tear film stability; preservative-free formulations avoid toxicity from benzalkonium chloride in frequent use. In ALSG, basal tearing is low or absent, so scheduled application (e.g., every 1–2 hours while awake) is often needed. Nighttime gel/ointment adds staying power during sleep to reduce morning blur and epithelial micro-damage. Notes: Keep a strict routine; blink fully; use humidity control and take screen breaks. Evidence: Artificial tears and lubricating ointments are first-line for dry eye and help reduce staining and symptoms in clinical trials and guidelines. EyeWiki

2. Moisture chamber glasses & environmental control.
   What/How: Wrap-around spectacles or silicone shields plus room humidifiers (aim ~40–50% RH). Purpose: Reduce tear evaporation and wind exposure. Mechanism: Creates a humid micro-environment in front of the eyes; decreasing airflow prevents rapid evaporation, a major cause of symptoms in aqueous-deficient dry eye. Evidence: Environmental and barrier strategies are recommended adjuncts in dry eye care to reduce evaporative loss and symptom burden. EyeWiki

3. Punctal occlusion (temporary plugs, then permanent if helpful).
   What/How: Tiny plugs inserted into the tear drainage openings to keep tears/teardrops on the eye longer. Purpose: Increase time that applied tears and any residual tears stay on the ocular surface. Mechanism: Blocks the outflow pathway (canaliculi) so the fluid you add does not drain away quickly. Notes: Works best when there is some fluid to retain (e.g., after you establish a frequent tear routine). Risks include extrusion or biofilm; permanent cautery is an option after a successful trial. Evidence: Tear conservation with punctal occlusion is a standard measure to reduce ocular surface staining and symptoms in aqueous deficiency. EyeWiki

4. Scleral lenses (PROSE or similar).
   What/How: Large rigid lenses vault over the cornea and hold a reservoir of sterile saline all day. Purpose: Continuous liquid bandage to protect and re-hydrate the ocular surface. Mechanism: The fluid reservoir shields the cornea from friction and evaporation and promotes epithelial healing. Evidence: Scleral devices are recommended for severe dry eye unresponsive to drops/ointments; cohorts show improved comfort, staining, and function. EyeWiki

5. Autologous or allogeneic serum eye drops.
   What/How: Eye drops made from your blood serum (or a donor’s if you cannot donate). Purpose: Provide epithelial growth factors, vitamins, and anti-inflammatory components closer to natural tears. Mechanism: Serum contains EGF, fibronectin, vitamin A, and cytokines that aid epithelial healing and nerve health. Evidence: Reviews and AAO technology assessments support use in severe dry eye and persistent defects, though heterogeneity limits firm conclusions; allogeneic serum can be comparable when autologous is not possible. EyeWiki+3PMC+3AAO+3

6. Lid hygiene & warm compress routines.
   What/How: Daily warm compresses and gentle lid massage; clean lid margins. Purpose: Optimize meibomian gland oil flow to slow evaporation. Mechanism: Heat liquefies meibum; massage expresses oils; cleaning reduces biofilm and inflammation. Evidence: Core component of dry eye regimens; improves tear film breakup time and symptoms. EyeWiki

7. Blink training and visual ergonomics.
   What/How: Set “blink cues,” 20-20-20 rule for screens, and adjust monitor height. Purpose: Prevent incomplete blinking and reduce exposure. Mechanism: Complete blinks spread oil and aqueous evenly; ergonomic changes limit evaporative stress. Evidence: Behavioral modifications appear in consensus guidance for evaporative and aqueous-deficient dry eye. EyeWiki

8. Dental fluoride care (toothpaste/varnish as directed).
   What/How: Twice-daily fluoride toothpaste; professional fluoride varnish per dentist. Purpose: Prevent cavities when saliva is low. Mechanism: Fluoride enhances enamel remineralization and resists acid attack. Evidence: Cochrane reviews confirm fluoride toothpaste prevents caries vs. non-fluoride; higher concentrations can increase benefit (balance with fluorosis risk in children). Cochrane Library+1

9. Sugar-free chewing gum or lozenges (xylitol preferred).
   What/How: Chew xylitol gum after meals if you still make some saliva. Purpose: Stimulate salivary flow and help reduce caries risk. Mechanism: Chewing provides gustatory/mechanical stimuli; xylitol is non-fermentable and may hinder Streptococcus mutans. Evidence: Trials show gum increases salivary flow and may improve xerostomia symptoms; caries reduction data for xylitol are mixed to modest—helpful adjunct, not a cure. PMC+2PMC+2

10. Saliva substitutes (sprays/gels with carboxymethylcellulose).
    What/How: Daytime sprays and thicker night gels. Purpose: Coat oral tissues, ease speaking/eating, and reduce soreness. Mechanism: CMC and similar polymers increase wetting and lubrication, mimicking saliva’s physical properties. Evidence: Trials show symptom relief in xerostomia, including after radiotherapy; CMC products often perform well. PMC+1

11. Frequent sipping and diet texture modification.
    What/How: Carry water, use sauces/gravies, avoid crumbly foods alone. Purpose: Make eating safer and more pleasant and prevent choking. Mechanism: External moisture replaces missing saliva lubrication. Evidence: Supportive measures feature prominently in xerostomia guidance. ASCO Publications

12. Rigorous dental recall (3–6-month intervals).
    What/How: Regular cleanings, early caries detection, custom trays for high-fluoride gel if prescribed. Purpose: Catch decay early and protect enamel. Mechanism: Professional surveillance plus fluoride lowers lesion progression. Evidence: Standard recommendations in dry-mouth care pathways. ASCO Publications

13. Treat oral candidiasis promptly when present.
    What/How: Dentist/physician evaluation for antifungals if burning mouth or erythema. Purpose: Reduce infection risk heightened by low saliva. Mechanism: Saliva has antimicrobial proteins; when absent, Candida overgrows. Evidence: Xerostomia guidelines stress vigilance for candidiasis. ASCO Publications

14. Blue-light/UV protection outdoors (wrap-around lenses).
    What/How: Sunglasses with side coverage. Purpose: Reduce photophobia and environmental irritants. Mechanism: Low tear volume exposes corneal nerves; light protection reduces symptoms. Evidence: Environmental shielding is endorsed for dry eye comfort. EyeWiki

15. Smoking cessation & alcohol moderation.
    What/How: Stop smoking; limit alcohol. Purpose: Both worsen ocular surface and dry mouth symptoms. Mechanism: Smoke irritates the surface and affects meibum; alcohol dehydrates and can suppress salivary flow. Evidence: Lifestyle risk factors appear across dry eye/xerostomia reviews. ASCO Publications

16. Humidified sleep and eyelid taping/shields at night if incomplete closure.
    What/How: Bedroom humidifier; soft eye shields; micropore taping for lagophthalmos. Purpose: Prevent overnight exposure keratopathy. Mechanism: Maintains moisture and limits air flow during sleep. Evidence: Conservative measures recommended for exposure-related dryness. EyeWiki

17. Nutritional oral care plan (low free sugar, frequent remineralization).
    What/How: Limit sugary snacks/drinks; rinse or brush soon after; use casein-phosphopeptide–amorphous calcium phosphate if advised. Purpose: Reduce caries drivers when saliva is low. Mechanism: Diet control lowers substrate for acidogenic bacteria; remineralization aids enamel. Evidence: Caries prevention frameworks prioritize sugar reduction and fluoride. Cochrane Library

18. Education and self-monitoring tools (OSDI, symptom logs).
    What/How: Track eye dryness and mouth dryness triggers. Purpose: Tailor routines and medication timing. Mechanism: Identifies patterns (screen time, AC exposure) to adjust behavior. Evidence: Patient-reported outcomes are standard in dry eye care and trials. EyeWiki

19. Physical therapy for jaw tightness and safe swallow training when needed.
    What/How: Referral to speech-language pathologist for dysphagia strategies. Purpose: Compensate for lack of lubrication. Mechanism: Swallow maneuvers and textures reduce aspiration risk. Evidence: Supportive in xerostomia care after head-neck therapy; principles generalize to severe dryness. ASCO Publications

20. Psychological support and adherence coaching.
    What/How: Set realistic routines; use reminders; consider support groups. Purpose: High-frequency eye/oral care is tiring; support improves adherence. Mechanism: Behavior change strategies maintain long-term self-care. Evidence: Adherence frameworks are key in chronic ocular surface disease management. EyeWiki

---

Drug treatments

1. Topical cyclosporine A (e.g., 0.05% emulsion; 0.09% solution).
   Class: Calcineurin inhibitor anti-inflammatory. Dose/Time: 1 drop in each eye twice daily; effects build over weeks. Purpose: Reduce ocular surface inflammation that worsens dryness damage. Mechanism: Inhibits T-cell activation and cytokine release on the ocular surface, improving tear film and corneal staining. Evidence: Multiple randomized trials (including classic 0.05–0.1% emulsions and newer 0.09–0.1% solutions) show improvements in signs/symptoms for moderate-to-severe dry eye; early effect with higher-strength water-free formulations reported. Side effects: Burning/stinging on instillation; rare hypersensitivity. JAMA Network+3PubMed+3AAO Journal+3

2. Lifitegrast 5% ophthalmic solution.
   Class: LFA-1 antagonist (anti-inflammatory). Dose/Time: 1 drop twice daily; symptom benefit can begin within 2 weeks in trials. Purpose: Reduce inflammation and improve eye dryness symptoms. Mechanism: Blocks LFA-1/ICAM-1 interaction, reducing T-cell–mediated inflammation. Evidence: Phase 2 and OPUS phase 3 trials show symptom/sign improvements, though regulatory reviews note heterogeneity across endpoints; it remains an accepted option in many practices. Side effects: Temporary instillation discomfort, dysgeusia (altered taste), irritation. FDA Access Data+3PubMed+3PubMed+3

3. Topical lubricating gels/ointments (night use).
   Class: Ocular surface lubricants (e.g., carbomer, petrolatum). Dose/Time: Bedtime; may blur vision. Purpose: Night protection and healing. Mechanism: Prolonged residence time reduces mechanical friction and evaporative loss overnight. Side effects: Temporary blur; preservative sensitivity if multidose bottles. Evidence: Standard supportive therapy in dry eye care pathways. EyeWiki

4. Topical corticosteroids (short pulses).
   Class: Anti-inflammatory steroid (e.g., loteprednol). Dose/Time: Short courses per ophthalmologist. Purpose: Calm flares of ocular surface inflammation. Mechanism: Broad cytokine suppression. Side effects: With prolonged use—IOP rise, cataract risk; therefore supervised, time-limited use only. Evidence: Short pulses are often used to “bridge” to slower-acting immunomodulators (like cyclosporine). EyeWiki

5. Antihistamine/mast-cell–stabilizer drops (if allergy coexists).
   Class: Antiallergic ocular agents. Dose/Time: Per label during allergy season. Purpose: Reduce itch/rub cycle that aggravates dryness. Mechanism: Stabilize mast cells; block histamine. Side effects: Mild sting; some products have BAK preservative—prefer PF when frequent. Evidence: Standard for allergic conjunctivitis; helpful adjunct if allergy triggers are present. EyeWiki

6. Topical antibiotics (only if infection).
   Class: Antibacterials. Dose/Time: Short course per culture/clinical suspicion. Purpose: Treat bacterial conjunctivitis/blepharitis when present. Mechanism: Eradicate pathogens. Side effects: Allergy, resistance risk—avoid chronic unsupervised use. Evidence: Standard ophthalmic practice when infection is diagnosed. EyeWiki

7. Autologous serum eye drops (compounded).
   Class: Biologic tear substitute. Dose/Time: Often 4–8×/day. Purpose/Mechanism: Growth factors and vitamins support epithelial/nerve health; can reduce staining and symptoms in severe disease. Side effects: Cold chain handling; rare contamination risk—use reputable compounding. Evidence: Systematic reviews and AAO assessments support use in severe dry eye/persistent epithelial defect. PMC+1

8. Allogeneic serum eye drops (when autologous not possible).
   Class: Donor-serum biologic. Dose/Time: Similar to autologous. Purpose/Mechanism: Same as above; allows access for patients unable to donate. Side effects: Screening/sterility essential. Evidence: EyeWiki summary notes comparable outcomes in some studies. EyeWiki

9. Pilocarpine (oral) for xerostomia.
   Class: Muscarinic agonist (secretagogue). Dose/Time: Commonly 5 mg PO three to four times daily with meals; titrate. Purpose: Increase saliva output if residual gland tissue exists. Mechanism: Stimulates M3 receptors on salivary acini. Side effects: Sweating, flushing, urinary frequency, nausea—start low/go slow. Evidence: Reviews and guidelines show symptom and flow benefits in therapy-induced and Sjögren-related xerostomia. PMC+1

10. Cevimeline (oral) for xerostomia.
    Class: Muscarinic M3-selective agonist. Dose/Time: Often 30 mg PO TID. Purpose/Mechanism: Similar to pilocarpine; may be better tolerated for some. Side effects: Sweating, GI upset; caution in asthma/cardiac arrhythmia. Evidence: Trials and recent analyses show improved flow and symptoms in xerostomia. ScienceDirect+1

11. Fluoride toothpaste (1,000–5,000 ppm as prescribed).
    Class: Topical anticaries agent. Dose/Time: Brush twice daily; high-fluoride paste/trays per dentist for high-risk adults. Purpose: Prevent enamel demineralization with low saliva. Mechanism: Promotes remineralization and acid resistance. Side effects: Fluorosis concern is for children; follow dental advice. Evidence: Strong Cochrane evidence vs. non-fluoride toothpaste. Cochrane Library

12. Antifungals (topical/oral) if candidiasis occurs.
    Class: Azoles, nystatin. Dose/Time: Per infection site/severity. Purpose: Treat oral thrush in very dry mouths. Mechanism: Inhibit fungal cell membranes. Side effects: Hepatic interactions (with azoles) — medical supervision needed. Evidence: Common management in xerostomia care pathways. ASCO Publications

13. Topical anesthetic mouth rinses (short-term).
    Class: Local anesthetics/benzydamine (where available). Dose/Time: PRN before meals. Purpose: Ease pain/burning to allow eating. Mechanism: Numbs inflamed mucosa; does not increase saliva. Side effects: Numbness—avoid biting cheek/tongue. Evidence: Symptomatic measure in xerostomia protocols. ASCO Publications

14. Enzymatic saliva sprays.
    Class: Lubricant + enzyme system. Dose/Time: Several times daily. Purpose: Reduce dryness and improve oral comfort. Mechanism: Viscosity + enzymes support lubrication and oral ecology. Side effects: Taste changes possible. Evidence: Recent RCTs suggest symptom improvements after radiotherapy. MDPI

15. Trehalose oral spray (vs. CMC).
    Class: Disaccharide moisturizing agent. Dose/Time: Several sprays/day. Purpose: Moisturize and raise saliva pH. Mechanism: Water retention and mucosal protection. Evidence: RCT showed increases in pH and saliva volume in radiation-induced xerostomia vs. CMC at 14 days. BioMed Central

16. Omega-3 fatty acids (oral) – with caution on expectations.
    Class: Nutraceutical anti-inflammatory. Dose/Time: Variable; discuss with clinician. Purpose: Anti-inflammatory support for ocular surface. Mechanism: n-3 eicosanoids may reduce ocular surface inflammation. Evidence: The large DREAM RCT (NEJM) did not find a significant benefit over placebo for dry eye—so these are optional, not core therapy. Side effects: GI upset; bleeding risk at high doses. New England Journal of Medicine

17. Topical antiseptics for plaque control (chlorhexidine mouthwash) – targeted use.
    Class: Antiseptic. Dose/Time: Short courses only if a dentist recommends. Purpose: Control plaque/gingivitis spikes when brushing is painful. Mechanism: Broad antimicrobial substantivity. Evidence: While CHX helps plaque/gingivitis, Cochrane reviews do not support it as a caries-prevention agent by itself; staining and taste disturbance limit long-term use. ScienceDirect+1

18. Topical vitamin A derivatives (ocular, specialist-guided).
    Class: Epithelial support. Dose/Time: As prescribed. Purpose: Promote corneal epithelial health. Mechanism: Supports goblet cells and mucins. Evidence: Incorporated within serum-based tear rationale; specialist use. PMC

19. Allergy control meds (oral, PF ocular) when triggers worsen dryness.
    Class: Antihistamines (choose least anticholinergic options). Dose/Time: As directed. Purpose: Reduce allergen-driven rubbing/tearing imbalance. Mechanism: Histamine blockade; prefer non-sedating, low anticholinergic agents to avoid extra mouth dryness. Evidence: Standard allergic eye care; choose agents thoughtfully in xerostomia. EyeWiki

20. Pain control for oral soreness (topicals/systemic, dentist-guided).
    Class: Analgesics as appropriate. Purpose: Enable eating/hygiene when mucosa is inflamed. Mechanism: Reduces pain perception. Evidence: Symptom-targeted adjunct in xerostomia plans. ASCO Publications

---

Dietary molecular supplements

(150-word descriptions with dosage, function, mechanism—always check interactions with your clinician.)

1. High-fluoride toothpaste/gel (1,500–5,000 ppm F⁻).
   Dose: Brush 2×/day; high-fluoride gel in trays as prescribed. Function: Strong enamel protection in low-saliva mouths. Mechanism: Fluoride forms fluorapatite and enhances remineralization; reduces demineralization during acid attacks. Evidence: Cochrane reviews support fluoride toothpaste for preventing caries vs. non-fluoride products. Cochrane Library

2. Xylitol (chewing gum/lozenges, total ~5–10 g/day).
   Function: Stimulates salivary flow; may reduce caries risk. Mechanism: Non-fermentable sugar alcohol that reduces acid production and may inhibit S. mutans. Evidence: Mixed—some reviews show modest benefit; others call evidence limited—use as an adjunct with fluoride and hygiene, not a stand-alone cure. Caution: GI upset at higher doses. Cochrane Library+1

3. Trehalose (oral spray).
   Dose: Per product (e.g., 10% spray, several times daily). Function: Moisturizing and mucosal protection. Mechanism: Stabilizes proteins and retains water; may raise saliva pH. Evidence: RCT found increased pH/volume vs. CMC after radiotherapy. BioMed Central

4. Electrolyte oral rehydration sips.
   Dose: Small, frequent sips. Function: Maintain hydration so any residual secretion works better. Mechanism: Supports fluid balance and mucosal moistening. Evidence: Common supportive advice in xerostomia care pathways. ASCO Publications

5. Vitamin D (optimize if deficient).
   Dose: As per lab results/clinician. Function: Bone/immune support; may reduce caries risk indirectly via enamel/bone health. Mechanism: Mineralization support. Evidence: General dental health literature supports deficiency correction; not specific to ALSG. ASCO Publications

6. Calcium and phosphate exposure (dietary; CPP-ACP if advised).
   Dose: Diet plus dentist-directed products. Function: Enamel remineralization. Mechanism: Provides ions to rebuild enamel subsurface. Evidence: Included in caries-risk reduction strategies alongside fluoride. Cochrane Library

7. Omega-3 fatty acids (optional, expectation-managed).
   Dose: Per clinician (e.g., 1–3 g/day combined EPA/DHA). Function: Systemic anti-inflammatory support. Mechanism: Modulates eicosanoids/cytokines. Evidence: DREAM RCT did not show superiority over placebo for dry eye; consider only as adjunct for other indications. New England Journal of Medicine

8. Probiotics (oral health strains; adjunct).
   Dose: Per product; consult dentist. Function: May modulate oral microbiome in high-caries risk. Mechanism: Compete with acidogenic bacteria. Evidence: Emerging—use only as supportive alongside fluoride and hygiene. ASCO Publications

9. Salivary enzyme systems (lactoperoxidase, etc.).
   Dose: In specific saliva substitutes/sprays. Function: Support antimicrobial activity. Mechanism: Mimic saliva’s enzyme defenses. Evidence: RCTs suggest symptom benefit with enzymatic sprays post-radiotherapy. MDPI

10. Caffeine moderation (negative supplement note).
    Dose: Limit high intake. Function: Avoid diuresis/dehydration that can worsen perceived dryness. Mechanism: Mild diuretic; may increase dryness sensation. Evidence: General supportive recommendation in xerostomia guidance. ASCO Publications

---

Immunity-booster / Regenerative / Stem-cell–oriented” drugs

1. Cenegermin (recombinant human Nerve Growth Factor) – ocular.
   What: FDA-approved for neurotrophic keratopathy; studied for severe dry eye. Dose: Eye drops per labeled regimen for NK (specialist-directed). Function/Mechanism: Promotes corneal nerve regeneration and epithelial healing; may help ocular surface where nerve compromise coexists. Evidence: Randomized trials show benefit in NK; early studies explore dry eye populations. Note: Not a standard ALSG therapy unless NK or refractory epithelial disease is present. PMC+1

2. Mesenchymal stem cell (MSC) injections to the lacrimal gland (investigational).
   Dose: Trial protocols only. Function/Mechanism: Aim to reduce inflammation and restore secretion through paracrine/trophic effects. Evidence: Early randomized trials in Sjögren dry eye report improvements; larger confirmatory studies are needed. PubMed

3. MSC-derived exosome eye drops (investigational).
   Dose: Research settings. Function/Mechanism: Deliver anti-inflammatory and regenerative signals to ocular surface. Evidence: Early clinical reports in Sjögren-associated dry eye suggest safety and symptom benefits; more trials required. PubMed+1

4. Umbilical cord-derived MSC eye drops (pilot studies).
   Dose: Research protocols. Function/Mechanism: Regenerative trophic support to cornea/ocular surface. Evidence: First-in-human pilot data emerging; not yet standard of care. BioMed Central

5. Biologic anti-inflammatory pathways (future).
   What: Novel topical cytokine-modulators under study. Function: Target ocular surface inflammation more precisely than current agents. Evidence: Ongoing trials; not yet established for ALSG-specific care. Frontiers

6. Systemic immune cell therapies (context only).
   What: MSC approvals exist for other diseases (e.g., pediatric GVHD), showing feasibility of cell-based therapies in general—but not indicated for ALSG. Caution: Do not extrapolate to ALSG without trials. Reuters

---

Surgeries

1. Submandibular salivary gland transplantation to the eye (for ocular dryness).
   Procedure: A surgeon moves a submandibular gland or its duct to supply fluid to the eye surface (with modifications/duct routing). Why: For the most severe, refractory dry eye where conventional therapy fails, transplanted saliva can substitute for tears to bathe the ocular surface. Evidence: Reviews and cohort studies report increased tear volume and stability; visual acuity may not change, and complications (mucus, epiphora, duct issues) require expert management. Note: Highly specialized. PubMed+2ScienceDirect+2

2. Minor salivary gland transplantation (to eyelids) – selected cases.
   Procedure: Small labial glands are transplanted to provide mucous secretions to the eye. Why: Alternative when submandibular transfer isn’t suitable. Evidence: Retrospective cohorts suggest viability in severe ocular surface disease; availability and expertise vary. PubMed

3. Permanent punctal occlusion (thermal cautery).
   Procedure: Permanently seals tear drains after a successful trial with plugs. Why: To conserve tears/lubricants long-term in profound aqueous deficiency. Evidence: Tear conservation is a cornerstone for severe aqueous-deficient states. EyeWiki

4. Tarsorrhaphy (partial eyelid closure) – vision-sparing.
   Procedure: Temporarily or permanently narrows the palpebral fissure. Why: Reduces exposure and evaporation for non-healing corneal epithelium. Evidence: Used in severe surface disease to protect the cornea when medical therapy is insufficient. EyeWiki

5. Amniotic membrane grafts for non-healing epithelial defects.
   Procedure: Biological bandage placed on the cornea. Why: Promotes healing, reduces inflammation, and protects nerves when dryness causes persistent defects. Evidence: Widely used in refractory ocular surface disease. EyeWiki

(Note: Because ALSG is a congenital absence problem, surgeries do not “create” lacrimal/salivary glands; they either conserve moisture or transplant tissues to substitute function.)

---

Preventions

1. Keep a strict, scheduled tear and gel routine—not just “as needed.” EyeWiki

2. Humidify home/work and shield eyes outdoors. EyeWiki

3. Limit screen time, follow blink breaks. EyeWiki

4. Twice-daily fluoride brushing, daily interdental cleaning; professional fluoride as advised. Cochrane Library

5. Low free-sugar diet and rinse/brush after sweets. Cochrane Library

6. Sugar-free gum/lozenges if residual saliva exists. PMC

7. Avoid smoking; moderate alcohol and caffeine. ASCO Publications

8. Address allergies that worsen eye rubbing/irritation. EyeWiki

9. Nighttime protection: gel + shields/taping for exposure. EyeWiki

10. Regular check-ups: ophthalmology and dentistry every 3–6 months. ASCO Publications

---

When to see a doctor urgently vs. routinely

Urgent (same day): sudden eye pain, light sensitivity with vision drop, a non-healing corneal spot/ulcer, trauma or chemical splash, severe mouth pain, feverish oral infection, or trouble swallowing liquids (aspiration risk). These may signal surface breakdown, infection, or ulcer needing immediate treatment. EyeWiki

Soon (days–weeks): worsening redness, increased tearing with discharge, new floaters/flashes, fast rise in dental pain/sensitivity, mouth cracks with white patches (possible candidiasis), or new medication causing extreme dryness. These need timely adjustment of therapy. ASCO Publications

Routine (every 3–6 months or as advised): symptom tracking, refills, pressure checks if using steroids, fluoride applications, bite-wings for caries surveillance, and lifestyle/diet review. PubMed+1

---

What to eat and what to avoid

1. Do eat: moist foods with sauces, soups, stews—easier to chew/swallow. Avoid: very dry, crumbly foods without liquid. ASCO Publications

2. Do: sip water or sugar-free beverages with meals. Avoid: frequent acidic/sugary drinks. Cochrane Library

3. Do: use xylitol gum/lozenges after meals if tolerated. Avoid: sugary candies that stick to teeth. PMC+1

4. Do: choose dairy/yogurt/cheese for buffering and minerals. Avoid: constant snacking on fermentable carbs. Cochrane Library

5. Do: ensure adequate vitamin D and calcium per clinician. Avoid: extreme diets that restrict essential nutrients. ASCO Publications

6. Do: prefer soft fruits and tender proteins. Avoid: spicy/acidic foods if they sting mucosa. ASCO Publications

7. Do: limit alcohol and caffeine if they worsen dryness. Avoid: mouth-drying energy drinks. ASCO Publications

8. Do: consider trehalose or enzymatic saliva sprays before meals for comfort. Avoid: mouthwashes with high alcohol content that sting. BioMed Central+1

9. Do: use fluoride toothpaste after breakfast and at night. Avoid: brushing immediately after acidic drinks—wait 30 minutes. Cochrane Library

10. Do: maintain balanced omega-3 intake from food if you like it. Avoid: assuming supplements will fix dry eye—the big RCT did not show benefit. New England Journal of Medicine

---

Frequently Asked Questions (FAQ)

1) Is ALSG the same as LADD syndrome?
They overlap but are not identical. ALSG features the lacrimal/salivary underdevelopment most strongly; LADD adds ear, dental, and finger differences. Both can involve FGF10-FGFR2/FGFR3 signaling. Genetic counseling helps families understand patterns. Nature+2MedlinePlus+2

2) How is ALSG diagnosed?
Doctors put together your symptoms, eye exam (e.g., Schirmer tear test, ocular surface staining), salivary measurements (sialometry), and imaging (ultrasound/MRI/CT) to look for absent or tiny glands. Genetic testing may confirm a pathogenic variant. PMC+3NCBI+3EyeWiki+3

3) What is the Schirmer test?
A tiny strip of paper is placed at the lower eyelid to measure tear production over five minutes. It helps grade aqueous deficiency. NCBI

4) What does “ocular surface staining” mean?
Doctors use dyes (fluorescein, lissamine green) to see dry spots and damage on the cornea/conjunctiva. It guides treatment intensity and progress. EyeWiki

5) Will my eyesight be lost from ALSG?
Severe dryness can damage the cornea, but with a layered plan—lubrication, tear conservation, anti-inflammatories, and protective measures—most people protect vision. Urgent care is needed for non-healing defects or infection. EyeWiki

6) Can medications make dryness worse?
Yes. Many common drugs (anticholinergics, antihistamines, some antidepressants) reduce salivary flow and can irritate eyes. Never stop a medication on your own; ask your prescriber for alternatives with less dry-mouth/eye effect. ASCO Publications

7) Are there cures to “grow” new glands?
No established therapy can regrow lacrimal/salivary glands in ALSG. Care focuses on replacement (artificial tears/saliva), conservation (plugs), anti-inflammation (topical immunomodulators), protection (scleral lenses), and, in selected cases, transplantation or protective surgeries. EyeWiki+1

8) Do serum eye drops really help?
They often help in severe cases by supplying growth factors similar to natural tears. Availability, cost, and handling are considerations. Evidence supports use, but studies vary; discuss with your cornea specialist. PMC+1

9) Are omega-3 supplements worth it?
Not reliably for dry eye. The large DREAM randomized trial found no significant benefit over placebo. Some people still choose them for general health, but they are optional here. New England Journal of Medicine

10) Which is better for dry mouth—pilocarpine or cevimeline?
Both increase flow if residual tissue exists. Cevimeline is M3-selective and may be better tolerated for some; pilocarpine is widely used. Try one with your clinician and switch if side effects limit use. PMC+1

11) Do xylitol gums prevent cavities?
They can help, mainly by boosting saliva and reducing bacterial acid production, but results across studies are mixed. Use xylitol as an adjunct—fluoride toothpaste and dental care remain the foundation. Cochrane Library

12) Are chlorhexidine mouthwashes good for cavity prevention?
Chlorhexidine helps plaque/gingivitis control but does not have strong evidence to prevent caries on its own; prolonged use can stain teeth and affect taste. Use only under dental guidance for specific reasons. Cochrane Library+1

13) Can stem cells cure ALSG?
Not at present. Early studies of MSC injections/exosomes are promising in autoimmune dry eye, but these are investigational and not ALSG-specific. Avoid unregulated clinics. PubMed+1

14) Is surgery an option for my dry eyes?
Only in the most severe, refractory cases. Options include permanent punctal occlusion, protective tarsorrhaphy, or specialized salivary gland transplantation to the eye. These are highly individualized. ScienceDirect

15) What specialists should I see?
A cornea specialist/ophthalmologist for eyes, a dentist familiar with xerostomia, and (when appropriate) a clinical geneticist. Coordinated care yields the best results. Genetic Diseases Center

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 20, 2025.